ArticleTranslational lung cancer research2026
Tumor-distant pulmonary immune landscapes are associated with postoperative outcomes in non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While antitumor immunity in lung cancer is typically evaluated within the tumor microenvironment and regional lymphoid organs, immune features in non-tumorous lung tissue-particularly at sites distant from the primary tumor-may also reflect host-related pulmonary immune characteristics. However, the clinical relevance of immune cell abundance in such tumor-distant lung parenchyma remains unclear. Therefore, this study aimed to investigate whether immune cell abundance in tumor-distant non-tumorous lung tissue is associated with clinicopathological features and postoperative outcomes in patients with non-small cell lung cancer (NSCLC). Methods: This retrospective observational study included 40 patients with NSCLC who underwent curative lobectomy and had paired tumor-near and tumor-distant lung tissue specimens available for analysis. Immunohistochemical staining for dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-positive cells and CD169-positive macrophages was performed, and immune cell counts were quantified using a hotspot counting method. Associations between immune cell counts, clinicopathological variables, smoking exposure, and recurrence-free survival (RFS) were analyzed. Results: Both DC-SIGN-positive cells and CD169-positive macrophages were significantly more abundant in tumor-near lung tissue than in tumor-distant tissue. However, only DC-SIGN-positive cell counts in tumor-distant lung parenchyma were associated with postoperative recurrence. Higher numbers of DC-SIGN-positive cells in tumor-distant specimens were associated with favorable RFS in univariate analysis, although this association did not remain statistically significant after propensity score (PS) adjustment, whereas immune cell counts in tumor-near tissue showed no clear association with postoperative outcomes. Tumor-distant DC-SIGN-positive cell counts were lower in patients with advanced pathological stage and tended to be reduced in those with lymph node metastasis. In contrast, CD169-positive macrophage counts were strongly associated with smoking exposure but were not related to RFS in either spatial compartment. Conclusions: Lower abundance of DC-SIGN-positive cells in tumor-distant, non-tumorous lung parenchyma was associated with more advanced pathological features and postoperative recurrence, suggesting inter-individual variability in pulmonary interstitial immune cell distribution beyond the tumor microenvironment. These findings support the possibility that inter-individual differences in tumor-distant pulmonary immune landscapes may be associated with advanced pathological features and postoperative recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.